FDA Brief

Warning letters Drugs

FDA warning letter to

Genesis Nutrition Ultra Slim dba Genesis Ultra Slim

High riskIssued Aug 6, 2021Posted Sep 7, 2021Office of Pharmaceutical Quality Operations, Division II

Genesis Nutrition Ultra Slim sells Genesis Ultra Slim Gold, a weight-loss product that contains undeclared sibutramine and phenolphthalein.

What happened

FDA reviewed the firm's websites and social media accounts between June and July 2021 and found claims that Genesis Ultra Slim Gold causes weight loss. Laboratory analysis of a sample of the product found undeclared sibutramine and phenolphthalein. FDA also issued a public warning telling consumers not to use the product. There was no facility inspection.

What FDA found

  1. The product is sold as a weight-loss drug without FDA approval, which makes it an unapproved new drug.

    Sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d)
  2. Because it contains sibutramine, the product cannot legally be sold as a dietary supplement.

    Section 201(ff)(3)(B)(ii) of the FD&C Act, 21 U.S.C. 321(ff)(3)(B)(ii)
  3. The label does not give adequate directions for safe use by an ordinary person.

    Section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1); 21 CFR 201.5
  4. The labeling is misleading because it does not disclose that the product contains sibutramine and phenolphthalein.

    Sections 502(a) and 201(n) of the FD&C Act, 21 U.S.C. 352(a) and 321(n)
  5. The labeling lacks adequate warnings to protect users.

    Section 502(f)(2) of the FD&C Act, 21 U.S.C. 352(f)(2)
  6. The product is dangerous to health when used as directed on the label.

    Section 502(j) of the FD&C Act, 21 U.S.C. 352(j)

What FDA wants

FDA asks the firm to write back within 15 working days describing each step taken to fix the violations and prevent them from recurring, with supporting documents; if the work is not finished, the firm must explain why and give a completion date.

Who should pay attention

  • retailers and online marketplaces that list weight-loss supplements
  • brands that buy or resell supplements from this firm
  • clinicians and consumers choosing weight-loss products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  2. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  3. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk
  4. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk